[186 Pages Report] The Antibody Therapeutics Market size was estimated at USD 248.79 billion in 2023 and expected to reach USD 285.77 billion in 2024, at a CAGR 14.89% to reach USD 657.50 billion by 2030.
Antibody therapeutics are a class of medical treatments that employ antibodies to mimic or enhance the immune system’s ability to fight diseases. The precision of antibody therapeutics allows for tailored treatments that provide high specificity and lower toxicity profiles than conventional drugs, making them effective in treating various conditions, including cancers, autoimmune diseases, and infectious diseases. The increasing incidences of chronic diseases and increased healthcare expenditure globally have increased the adoption of antibody therapeutics. However, high costs associated with development and lengthy and complex regulatory approvals limit the penetration of antibody therapeutics. Nevertheless, advancements in medical technology are leading to more productive antibody production. In addition, the emergence of next-generation antibodies and supportive government initiatives for cancer care and treatments are expected to offer potential opportunities for the antibody therapeutics market.
Format: Significant utilization of monoclonal antibodies due to numerous approvals by regulatory agencies for clinical use
Antibody fragments are smaller constituents of a full-length antibody that retains antigen-binding activity. Antibody fragments include single-chain variable fragments (scFvs), antigen-binding fragments (Fabs), and variable fragment (Fv) domains. Antibody fragments offer advantages such as better tumor penetration and reduced immunogenicity, making them useful in therapeutic applications where a whole antibody structure might be less effective or appropriate. Bispecific antibodies (BsAbs) are engineered proteins capable of simultaneously binding to two different antigens or epitopes. This dual affinity allows BsAbs to engage multiple targets, such as cancer and immune cells, thus facilitating targeted cell killing. Bispecific antibodies have diverse applications in cancer therapy, particularly in recruiting immune cells to tumor cells to enhance the immune response against cancer. Monoclonal antibodies (mAbs) are similar and produced by a single clone of cells, targeting a specific epitope. Monoclonal antibodies are widely used in therapies for cancer, autoimmune diseases, infectious diseases, and more due to their high specificity. Monoclonal antibodies have become one of the major forms of biologics in therapeutic uses, with numerous mAbs approved by regulatory agencies for clinical use. Polyclonal antibodies are collections of antibodies originating from different immune cell lines and consequently recognize multiple epitopes on an antigen.
Route of Administration: Growing usage of intravenous administration of antibody therapeutics
Intravenous administration is a common route for delivering antibody therapeutics directly into the bloodstream. This method ensures immediate bioavailability, supporting rapid therapeutic action. During IV administration, therapeutic antibodies are administered by a healthcare professional via an IV line, which allows for precise control over the dosage and rate of infusion. Intravenous administration is often preferred for antibodies with larger molecular sizes or when high doses are required. Subcutaneous administration is an alternative route to inject antibody therapeutics into the fatty tissue layer beneath the skin. This method provides the convenience of self-administration, the potential for reduced healthcare costs, and improved patient quality of life. Subcutaneous administration is commonly used for chronic conditions requiring long-term treatment.
Source: Increasing use of human antibodies due to its biocompatible nature
Chimeric antibodies are engineered monoclonal antibodies composed of murine variable regions, which are the parts that bind to the antigen, and human constant regions. This genetic modification is intended to reduce the immunogenicity of the antibody when used in humans. Chimeric antibodies are preferred when a quick development is necessary, considering the murine components can be developed. Compared to human and humanized antibodies, chimeric antibodies generally have a higher potential for immunogenicity but can be produced more rapidly. Human antibodies are fully derived from human gene sequences. Human antibodies are the most biocompatible type, with minimal risk of causing an immune response when administered to patients. Human antibodies are preferred for longer-term treatments due to their low immunogenicity. The development process of human antibodies can be more complex and time-consuming, which may influence decision-making based on the urgency of the therapeutic need. Humanized antibodies are similar to chimeric antibodies but have more human genetic sequences. Humanized antibodies are often used to balance reduced immunogenicity and efficient development timelines, serving as a compromise between chimeric and human antibodies.
Disease Areas: Proliferating use of antibody therapeutics for infectious diseases
Antibody therapeutics for autoimmune and inflammatory diseases aim to modulate the immune system to decrease inflammation and prevent tissue damage. These biologics target specific cell surface markers or soluble mediators such as cytokines (TNF-?, IL-6) implicated in rheumatoid arthritis, psoriasis, and inflammatory bowel disease. In hematology, antibody therapeutics treat various blood disorders, including anemias, clotting disorders, and hematological malignancies. The antibodies used in hematology may be designed to target specific antigens on cancer cells or to modulate coagulation pathways. Immunology-focused antibody therapeutics are geared towards diseases wherein the immune response is defective, such as in primary immunodeficiency disorders or organ transplantations where immune rejection is a risk. Antibody therapeutics in infectious diseases serve as prophylactic and treatment options, particularly for viral and bacterial pathogens resistant to traditional small-molecule drugs. The antibodies for infectious diseases can neutralize pathogens or tag them for destruction by the immune system. Neurological antibodies are a relatively new therapeutic area, mainly addressing neurodegenerative conditions, including Alzheimer’s disease and multiple sclerosis. Treatment goals often include reducing aberrant protein aggregates or modulating the immune response in multiple sclerosis. Antibody therapeutics have transformed cancer treatment by targeting tumor-associated antigens, thereby inhibiting tumor growth and recruitment of immune effector functions. Within osteology, antibody therapeutics focus on bone diseases, most notably osteoporosis, by targeting bone remodeling pathways.
End User: Evolving usage of antibody therapeutics in hospitals
Hospitals represent a significant end-user for antibody therapeutics, catering to patients with acute and chronic conditions. The need-based preference for antibody therapeutics in hospitals is primarily dictated by their ability to provide immediate, specialized, and intensive care. Patients treated at hospitals often require immediate attention for severe illnesses, and antibody therapeutics can offer targeted treatment for conditions such as autoimmune diseases, cancers, and infectious diseases. Long-term care facilities serve an older population or individuals with prolonged health conditions that require sustained medical care and assistance. In long-term care settings, the need-based preference for antibody therapeutics is often for managing chronic diseases, such as Alzheimer’s or certain types of cancers. Antibody therapeutics in long-term care facilities generally focus on improving the quality of life and extending the functional independence of residents.
Regional Insights
In the Americas, antibody therapeutics market exhibit robust growth supported by a well-established R&D ecosystem, extensive patent portfolio, and high healthcare expenditure. Furthermore, the Americas includes numerous biopharmaceutical giants, which dedicate substantial resources to developing monoclonal antibodies and novel drug discovery. The Asia-Pacific region experienced a surge in the need for antibody therapeutics due to a growing healthcare infrastructure and increased incidences of chronic disease. Moreover, the Asia-Pacific region is witnessing growth in the antibody therapeutics market owing to the advances in personalized medicine and antibody development, supported by its strong research institutions and supportive government policies. Given their strong pharmaceutical industry, extensive research initiatives, and comprehensive intellectual property rights framework, European Union countries are pivotal in the antibody therapeutics landscape. In addition, countries in the Middle East and Africa are investing in state-of-the-art medical facilities and healthcare innovation.
FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the Antibody Therapeutics Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Antibody Therapeutics Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Key Company Profiles
The report delves into recent significant developments in the Antibody Therapeutics Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., AbCellera Biologics Inc., Adaptimmune Therapeutics PLC, ADC Therapeutics SA, Aenova Holding GmbH, Almac Group Limited, Amgen Inc., Antikor Biopharma, Argenx SE, Astellas Pharma Inc., AstraZeneca PLC, Baxter International Inc., Bayer AG, Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Biogen Inc., BioNTech SE, Bristol-Myers Squibb Company, Confo Therapeutics, DH Life Sciences, LLC, DotBio Pte. Ltd., Eli Lilly and Company, Emergent BioSolutions Inc., Evonik Industries AG, F. Hoffmann-La Roche Ltd., GE HealthCare Technologies, Inc.,, Genmab A/S, GlaxoSmithKline PLC, Grifols, S.A., Incyte Corporation, iTeos Therapeutics, Inc., Johnson & Johnson Services, Inc., Merck KGaA, Merus N.V., MoonLake Immunotherapeutics AG, MorphoSys AG, Novartis AG, Novo Nordisk A/S, Numab Therapeutics AG, Pfizer Inc., PharmAbcine Inc., Pyxis Oncology, Inc., Regeneron Pharmaceuticals, Inc., SAB Biotherapeutics, Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, Thermo Fisher Scientific Inc., TRIO Pharmaceuticals Inc., UCB S.A., and Xencor, Inc..
Market Segmentation & Coverage
This research report categorizes the Antibody Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:
- Format
- Antibody Fragment
- Bispecific Antibody
- Monoclonal Antibody
- Polyclonal Antibody
- Route of Administration
- Intravenous
- Subcutaneous
- Source
- Chimeric
- Human
- Humanized
- Disease Areas
- Autoimmune & Inflammatory Diseases
- Hematology
- Immunology
- Neurology
- Oncology
- Osteology
- End User
- Hospitals
- Long-term Care Facilities
- Region
- Americas
- Argentina
- Brazil
- Canada
- Mexico
- United States
- California
- Florida
- Illinois
- New York
- Ohio
- Pennsylvania
- Texas
- Asia-Pacific
- Australia
- China
- India
- Indonesia
- Japan
- Malaysia
- Philippines
- Singapore
- South Korea
- Taiwan
- Thailand
- Vietnam
- Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom
- Americas
The report offers valuable insights on the following aspects:
- Market Penetration: It presents comprehensive information on the market provided by key players.
- Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
- Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
- Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
- Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
The report addresses key questions such as:
- What is the market size and forecast of the Antibody Therapeutics Market?
- Which products, segments, applications, and areas should one consider investing in over the forecast period in the Antibody Therapeutics Market?
- What are the technology trends and regulatory frameworks in the Antibody Therapeutics Market?
- What is the market share of the leading vendors in the Antibody Therapeutics Market?
- Which modes and strategic moves are suitable for entering the Antibody Therapeutics Market?
US $
Euro €
GBP £
